Mesa County Sheriff's Office introduces new AngelSense Program
MESA COUNTY, Colo. (KREX) – The Mesa County Sheriff's Office is launching a new safety initiative called the AngelSense Program.
The program is committed to helping quickly locate and recover residents at risks of wandering due to conditions like autism, dementia, Alzheimer's and other developmental disabilities or medically induced cognitive conditions.
The new program comes from a partnership with AngelSense, which supplies technology for people with disabilities or conditions that could affect cognitive abilities.
Said technology are things like a wearable device that has an auto-pickup speakerphone as well as an SOS button, a proactive monitoring and alerting system and application for caregivers.
With help from the Colorado Bureau of Investigation and its Persons Who Wander Grant, the sheriff's office has already provided 22 wearable AngelSense devises to those at risks of wandering. The devices send a location updates every 10 seconds from any distance.
If those at risk of wandering do get lost, caregivers or loved ones can provide a link to law enforcement which gives them an up-to-date location helping to find the individual in timely manner.
'We are excited to offer this program to our community members in Mesa County,' said MCSO Sgt. Ross Young. 'It has been a team effort to select a service provider that we believe will improve the ability for law enforcement to locate individuals at-risk of wandering in our community should they become lost. While we never hope to need this technology, we look forward to seeing AngelSense in action to help locate these individuals quickly.'
For those curious in the latest technology, applications to an enrollment process can be submitted through the Mesa County Sheriff's website. After the application is received, specialists will review it and contact the person behind the submission for interview to finalize the enrollment process.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Tips to take care of your brain for Alzheimer's and Brain Health Awareness Month
June is Alzheimer's and Brain Health Awareness Month and people hoping to spread that awareness said there are things you can do to take charge of your brain health. Brain changes that cause Alzheimer's can begin 20 years or more before symptoms appear. Work to start on Rockdale Road next week Doing things like exercising, eating right, getting good quality sleep, and controlling blood pressure can improve brain health and reduce the risk of cognitive decline. While age and family history are factors, these can naturally help you to reduce your risk. Millcreek man says over $1000 was stolen from EBT account 'It's not just the individual with the diagnosis, but it's the over 480 thousand caregivers here in the state of Pennsylvania that are providing that care. It's the family members that are in that circle of care who need that information and support. We want people to know they're not alone,' said Sara Murphy, vice president of programs and services for the Alzheimer's Association Greater PA Chapter. Early detection of cognitive diseases is crucial. The Alzheimer's Association also has a help line that anyone can call to get support at 1-800-272-3900. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
11 hours ago
- Yahoo
Blood test for Alzheimer's could soon be available on the NHS
A new blood test for Alzheimer's disease has been found to accurately detect early symptoms of the illness, according to new research. Experts from the Mayo Clinic in the US examined two proteins in blood plasma – amyloid beta 42/40 and p-tau217 – which are associated with amyloid plaque build-up, a hallmark of Alzheimer's disease, to provide further evidence that blood tests can accurately diagnose dementia. The study, which was carried out on more than 500 people in an outpatient memory clinic, found the blood test was highly accurate, with 95 per cent sensitivity. That means it was 95 per cent accurate in picking up people with memory problems, with very few cases missed. It was also 82 per cent for specificity, meaning it was also highly accurate in ruling out people without dementia. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting.'
Yahoo
17 hours ago
- Yahoo
The Cause of Alzheimer's Might Be Coming From Within Your Mouth
In recent years, an increasing number of scientific investigations have backed an alarming hypothesis: Alzheimer's disease may not be merely a condition of an aging brain, but the product of infection. While the exact mechanisms of this infection are something researchers are still trying to isolate, numerous studies suggest the deadly spread of Alzheimer's goes way beyond what we used to think. One such study, published in 2019, suggested what could be one of the most definitive leads yet for a bacterial culprit behind Alzheimer's, and it comes from a somewhat unexpected quarter: gum disease. Watch the video below for a summary of their study: In a paper led by senior author Jan Potempa, a microbiologist from the University of Louisville, researchers reported the discovery of Porphyromonas gingivalis – the pathogen behind chronic periodontitis (aka gum disease) – in the brains of deceased Alzheimer's patients. It wasn't the first time the two factors have been linked, but the researchers went further. In separate experiments with mice, oral infection with the pathogen led to brain colonization by the bacteria, together with increased production of amyloid beta (Aβ), the sticky proteins commonly associated with Alzheimer's. The research team, coordinated by pharma startup Cortexyme, which was co-founded by first author Stephen Dominy, wasn't claiming to have discovered definitive evidence of Alzheimer's causation. But it was clear they thought we had a strong line of investigation here. P. gingivalis' gingipains (red) among neurons in the brain of a patient with Alzheimer's. (Cortexyme) "Infectious agents have been implicated in the development and progression of Alzheimer's disease before, but the evidence of causation hasn't been convincing," Dominy said at the time. "Now, for the first time, we have solid evidence connecting the intracellular, Gram-negative pathogen, P. gingivalis, and Alzheimer's pathogenesis." In addition, the team identified toxic enzymes called gingipains secreted by the bacteria in the brains of Alzheimer's patients, which correlated with two separate markers of the disease: the tau protein, and a protein tag called ubiquitin. But even more compellingly, the team identified these toxic gingipains in the brains of deceased people who were never diagnosed with Alzheimer's. That's important, because while P. gingivalis and the disease have been linked before, it's never been known – to put it simply – whether gum disease causes Alzheimers, or whether dementia leads to poor oral care. The fact that low levels of gingipains were evident even in people who were never diagnosed with Alzheimer's could be a smoking gun – suggesting they might have developed the condition if they had lived longer. "Our identification of gingipain antigens in the brains of individuals with AD and also with AD pathology but no diagnosis of dementia argues that brain infection with P. gingivalis is not a result of poor dental care following the onset of dementia or a consequence of late-stage disease, but is an early event that can explain the pathology found in middle-aged individuals before cognitive decline," the authors explained in their paper. Further, a compound formulated by the company called COR388, showed in experiments with mice that it could reduce bacterial load of an established P. gingivalis brain infection, while also reducing amyloid-beta production and neuroinflammation. We'll have to wait and see what future research will uncover about this link, but the research community is cautiously optimistic. "Drugs targeting the bacteria's toxic proteins have so far only shown benefit in mice, yet with no new dementia treatments in over 15 years it's important that we test as many approaches as possible to tackle diseases like Alzheimer's," chief scientific officer David Reynolds from Alzheimer's Research commented in a statement. The findings were reported in Science Advances. An earlier version of this story was published in January 2019. Common Diabetes Drug Linked to 'Exceptional Longevity' in Women Increased Toxicity Risk Identified For Children With ADHD, Autism Coffee Could Be The Secret to Healthy Aging For Women, Scientists Discover
